All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 23, 2023
Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
Cardiovascular, BioWorld Science RSS Feed RSS

Heart and DNA
Biomarkers

Rs2019090 polymorphism tied to coronary artery disease risk

Feb. 24, 2023
No Comments
Coronary artery disease (CAD) will likely remain the worldwide leading cause of death for the next couple of decades. Genome-wide association studies (GWAS) have been useful to identify hundreds of genomic loci that contribute CAD risk.
Read More
Cardiovascular

Zoetis Services discovers 5-HT2B receptor antagonists for heart failure

Feb. 23, 2023
No Comments
Zoetis Services LLC has described 5-HT2B receptor antagonists reported to be useful for the treatment of heart failure.
Read More
3D illustration of heart cross section
Cardiovascular

Preclinical profile of novel cardiac myosin inhibitor CK-586 disclosed

Feb. 23, 2023
No Comments
Hypertrophic cardiomyopathy (HCM) is an inherited disorder where different mutations in cardiac myosin lead to hypercontractility of...
Read More
Blood clot blocking a blood vessel
Cardiovascular

BB-031, a new aptamer inhibitor of VWF with efficacy in canine large vessel occlusion stroke model

Feb. 16, 2023
No Comments
Researchers from Basking Biosciences Inc. presented preclinical data for BB-031, a novel RNA aptamer that binds and inhibits Von Willebrand Factor (VWF). BB-031 (0.5, 1.0 and 5.0 mg/kg) or placebo were administered to a canine model of large vessel occlusion (LVO) stroke at 6 hours post-LVO with an autologous clot.
Read More
Hemorrhagic stroke concept art
Cardiovascular

New mouse model of IVH shows local inflammation and no cognitive impairment

Feb. 15, 2023
No Comments
Scientists from the National Institutes of Health and affiliated organizations established a novel mouse model of intraventricular extension of hemorrhage (IVH) for the purpose of measuring motor and cognitive function in acute and chronic stages of intracerebral hemorrhage, which is the most severe stroke subtype.
Read More
Heart cross section
Cardiovascular

In heart failure, metabolic alterations precede dysfunction

Feb. 15, 2023
By Anette Breindl
No Comments
Heart failure is a common condition: according to a new study in 11 high-income countries, an estimated 1-2% of the population has heart failure. One feature of late-stage heart failure is nicotine adenine dinucleotide (NAD+), which leaves heart muscle cells unable to generate sufficient ATP to meet their energy needs. Now, investigators at The Hospital for Sick Children and the University of Toronto have shown that this metabolic dysfunction is present early in heart failure, and precedes any sign of clinical dysfunction in the heart.
Read More
Heart scientific overlay
Cardiovascular

Sequana completes preclinical studies with DSR 2.0 for congestive heart failure

Feb. 8, 2023
No Comments
Sequana Medical NV has completed GLP animal studies, demonstrating the safety of its second-generation DSR (direct sodium removal) product (DSR 2.0) for congestive heart failure, following chronic exposure.
Read More
Cholesterol plaque in artery
Cardiovascular

T-cell study reveals autoimmune component of atherosclerosis

Jan. 31, 2023
By Mar de Miguel
No Comments
The combination of two sequencing techniques has unveiled features of a subpopulation of cells that could be producing plaques in atherosclerosis. This process is associated with an autoimmune component driven by CD4+ T cells, according to a study from researchers at Leiden University.

“I think that we can clearly say now that atherosclerosis is a very clear autoimmune component. It is a multifactorial disease, a combination of genes, and lifestyle, but also inflammation and the immune system,” Ilze Bot and Bram Slütter, associate professors at the Division of Biotherapeutics of Leiden University, told BioWorld.
Read More
Cardiovascular

Shengke Pharmaceuticals (Jiangsu) patents new PCSK9 inhibitors

Jan. 31, 2023
No Comments
Shengke Pharmaceuticals (Jiangsu) Ltd. has described proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of atherosclerosis, myocardial infarction, nonalcoholic steatohepatitis, stroke, type 2 diabetes, dyslipidemia, hyperphosphatemia and diabetic nephropathy.
Read More
3D heart in chest
Cardiovascular

China's CDE clears IND for Help's iPS cell-derived cardiomyocyte therapy for ischemic heart failure

Jan. 31, 2023
No Comments
Help Therapeutics Co. Ltd. has received IND approval from China's Center for Drug Evaluation (CDE) for HiCM-188.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 810 811 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 23, 2022.
  • Woman with headache

    Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

    BioWorld
    Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Targets with arrows

    Flagship puts $50M toward targeted tissue-homing tech startup

    BioWorld
    In an ideal world, when a patient takes a medicine, it acts only at the specific site of disease in the human body whilst sparing healthy tissues. But it almost...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing